In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
The closing price of CytomX Therapeutics Inc (NASDAQ: CTMX) was $1.67 for the day, down -3.47% from the previous closing price of $1.73. In other words, the price has decreased by -$3.47 from its previous closing price. On the day, 0.51 million shares were traded. CTMX stock price reached its highest trading level at $1.745 during the session, while it also had its lowest trading level at $1.635.
Ratios:
Our analysis of CTMX’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 1.17 and its Current Ratio is at 1.17.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, BMO Capital Markets on November 14, 2022, Downgraded its rating to Market Perform and sets its target price to $2.60 from $3 previously.
On July 07, 2022, Wedbush Downgraded its rating to Neutral which previously was Outperform and also lowered its target price recommendation from $6 to $2.
Piper Sandler Downgraded its Overweight to Neutral on July 07, 2022, whereas the target price for the stock was revised from $10 to $1.50.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Mar 19 ’24 when McCarthy Sean A. sold 20,223 shares for $2.09 per share. The transaction valued at 42,175 led to the insider holds 524,481 shares of the business.
BELVIN MARCIA sold 12,795 shares of CTMX for $26,684 on Mar 19 ’24. The SVP, Chief Scientific Officer now owns 168,579 shares after completing the transaction at $2.09 per share. On Mar 19 ’24, another insider, Landau Jeffrey B, who serves as the Chief Business Officer of the company, sold 6,562 shares for $2.09 each. As a result, the insider received 13,685 and left with 110,060 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CTMX now has a Market Capitalization of 113112104 and an Enterprise Value of -47439832. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.12. Its current Enterprise Value per Revenue stands at -0.469 whereas that against EBITDA is 11.009.
Stock Price History:
The Beta on a monthly basis for CTMX is 1.09, which has changed by 0.024539828 over the last 52 weeks, in comparison to a change of 0.2006725 over the same period for the S&P500. Over the past 52 weeks, CTMX has reached a high of $2.86, while it has fallen to a 52-week low of $1.04. The 50-Day Moving Average of the stock is -17.47%, while the 200-Day Moving Average is calculated to be 3.99%.
Shares Statistics:
CTMX traded an average of 924.28K shares per day over the past three months and 690950 shares per day over the past ten days. A total of 67.31M shares are outstanding, with a floating share count of 66.42M. Insiders hold about 1.92% of the company’s shares, while institutions hold 48.26% stake in the company. Shares short for CTMX as of 1711584000 were 3323519 with a Short Ratio of 3.60, compared to 1709164800 on 1637589. Therefore, it implies a Short% of Shares Outstanding of 3323519 and a Short% of Float of 4.95.
Earnings Estimates
The stock of CytomX Therapeutics Inc (CTMX) is currently in the spotlight, with 5 analysts actively rating and assessing its market standing.On average, analysts expect EPS of -$0.05 for the current quarter, with a high estimate of $0.02 and a low estimate of -$0.22, while EPS last year was -$0.05. The consensus estimate for the next quarter is -$0.02, with high estimates of $0.01 and low estimates of -$0.05.
Analysts are recommending an EPS of between $0.04 and -$0.48 for the fiscal current year, implying an average EPS of -$0.19. EPS for the following year is -$0.37, with 5 analysts recommending between -$0.12 and -$1.11.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 5 analysts. It ranges from a high estimate of $27M to a low estimate of $15M. As of the current estimate, CytomX Therapeutics Inc’s year-ago sales were $23.5M, an estimated decrease of -4.60% from the year-ago figure.
A total of 4 analysts have provided revenue estimates for CTMX’s current fiscal year. The highest revenue estimate was $108M, while the lowest revenue estimate was $80M, resulting in an average revenue estimate of $90.55M. In the same quarter a year ago, actual revenue was $101.21M, down -10.50% from the average estimate. Based on 5 analysts’ estimates, the company’s revenue will be $77.48M in the next fiscal year. The high estimate is $108M and the low estimate is $26M. The average revenue growth estimate for next year is down -14.40% from the average revenue estimate for this year.
